Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public? - BIO International Convention

Webinar Sponsor

Within the past year the role in biotech of special purpose acquisition companies (SPAC) has moved from a rarefied interest to a core option for reaching public markets, now attracting high levels of investor and regulator attention. Learn through live Q&A with a panel of SPAC deal experts how this popular, volatile tool for raising capital works in practice and will evolve next. The session also opens with a preview of BIO Digital's finance and business development educational programming.

Moderated by:
Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, Pharmaceutical Executive; Senior Advisor, EY

Panelists:
Jonas Grossman, President and Managing Partner, Chardan
Rakhi Kumar, Chief Accounting Officer, Roivant Sciences
Ryan Maierson, Partner, Latham & Watkins LLP
Carlo Passeri, Director, Biotechnology Capital Markets, Biotechnology Innovation Organization (BIO)

View the webinar with an expert panel of SPAC deal experts from EY, Chardan, Roivant Sciences, Latham & Watkins, and BIO as they discuss how this popular, volatile tool for raising capital works in practice and how it will evolve next

View Webinar